RecruitingPhase 1Drug trial
Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults
Researchers are testing an investigational medicine called ALZ-507 in healthy adults between 50 and 75 years of age.
The purpose of this study is to learn:
Assess if oral ALZ-507 is safe What side effects may occur How the body absorbs ALZ-507 Whether food affects how ALZ-507 is absorbed How much ALZ-507 reaches the blood, cerebrospinal fluid, and urine
Participants will receive either ALZ-507 or a placebo. Some participants will receive a single dose, while others will receive daily doses for two weeks. Researchers will monitor participants closely through medical examinations, laboratory testing, and collection of blood, cerebrospinal fluid and urine.
The findings from this study will help guide the future development of ALZ-507.
The information from this study will help determine whether ALZ-507 is safe for further clinical development.